Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Vontobel Holding Ltd.

Vontobel Holding Ltd. raised its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 13.6% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 7,339 shares of the biopharmaceutical company's stock after purchasing an additional 881 shares during the quarter. Vontobel Holding Ltd.'s holdings in Regeneron Pharmaceuticals were worth $4,655,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also bought and sold shares of REGN. Brighton Jones LLC raised its stake in shares of Regeneron Pharmaceuticals by 261.8% in the fourth quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company's stock valued at $675,000 after acquiring an additional 686 shares during the period. US Bancorp DE increased its position in Regeneron Pharmaceuticals by 21.6% during the 4th quarter. US Bancorp DE now owns 6,066 shares of the biopharmaceutical company's stock valued at $4,321,000 after purchasing an additional 1,078 shares during the period. Jones Financial Companies Lllp increased its position in Regeneron Pharmaceuticals by 107.7% during the 4th quarter. Jones Financial Companies Lllp now owns 812 shares of the biopharmaceutical company's stock valued at $578,000 after purchasing an additional 421 shares during the period. Steward Partners Investment Advisory LLC increased its position in Regeneron Pharmaceuticals by 26.9% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 4,627 shares of the biopharmaceutical company's stock valued at $3,296,000 after purchasing an additional 981 shares during the period. Finally, Commerzbank Aktiengesellschaft FI increased its position in Regeneron Pharmaceuticals by 49.5% during the 4th quarter. Commerzbank Aktiengesellschaft FI now owns 601 shares of the biopharmaceutical company's stock valued at $423,000 after purchasing an additional 199 shares during the period. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Price Performance

Shares of Regeneron Pharmaceuticals stock traded down $9.25 during trading hours on Monday, reaching $538.11. 959,668 shares of the company's stock were exchanged, compared to its average volume of 907,598. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $1,211.20. The company has a market capitalization of $58.10 billion, a P/E ratio of 13.70, a price-to-earnings-growth ratio of 2.00 and a beta of 0.33. The business has a fifty day moving average of $547.93 and a two-hundred day moving average of $623.60. The company has a quick ratio of 4.03, a current ratio of 4.93 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing the consensus estimate of $8.83 by ($0.61). The firm had revenue of $3.03 billion for the quarter, compared to analyst estimates of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. The company's revenue was down 3.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $9.55 EPS. As a group, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th were given a dividend of $0.88 per share. The ex-dividend date of this dividend was Tuesday, May 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.65%. Regeneron Pharmaceuticals's payout ratio is 8.96%.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. The Goldman Sachs Group lowered their price target on shares of Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating on the stock in a report on Wednesday, April 30th. Guggenheim reiterated a "buy" rating on shares of Regeneron Pharmaceuticals in a research note on Friday, May 30th. Wall Street Zen lowered Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 1st. Truist Financial decreased their price objective on shares of Regeneron Pharmaceuticals from $975.00 to $940.00 and set a "buy" rating for the company in a research note on Wednesday, April 30th. Finally, Bank of America decreased their price objective on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating for the company in a research note on Thursday, April 17th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, sixteen have issued a buy rating and three have given a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $822.58.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.